Pfizer (PFE)
30.52
+0.52 (1.73%)
NYSE · Last Trade: Nov 4th, 12:00 PM EST
News & Press Releases
Pfizer: 3 Key Takeaways for Long-Term Investorsfool.com
The patent-expiry question is still open: whether cutting costs now buys enough time for late-stage trials to replace fading blockbuster revenue.
Via The Motley Fool · November 4, 2026
Pfizer Q3 Earnings Call Highlightsmarketbeat.com
Pfizer (NYSE:PFE) reported third-quarter 2026 revenue of $16.6 billion and raised its full-year outlook, citing growth in non-COVID products, contributions from launched and acquired medicines, and continued cost-control efforts.
Chief Executive Officer Albert Bourla said the company’s launched and
Via MarketBeat · November 4, 2026
PFE Q3 deep dive: new product momentum offsets margin compression, guidance raised for 2026
Global pharmaceutical company Pfizer (NYSE:PFE) reported revenue ahead of Wall Street’s expectations in Q3 2026, but sales were flat year on year at $16.58 b...
Via StockStory · November 4, 2026
AMRX Q3 deep dive: biosimilars and specialty launches expand growth engines, guidance raised
Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) reported Q3 2026 results beating Wall Street’s revenue expectations, with sales up 10% year on ye...
Via StockStory · November 4, 2026
Pfizer (NYSE:PFE) Beats Q3 2026 Estimates and Raises Full-Year Outlook as New Products Offset COVID Declineschartmill.com
Via Chartmill · November 3, 2026
Earnings to watch: Zoetis (ZTS) reports Q3 results tomorrow
Animal health company Zoetis (NYSE:ZTS) will be reporting earnings this Thursday before market hours. Here’s what to look for. Zoetis missed analysts’ revenu...
Via StockStory · November 3, 2026
Collegium Pharmaceutical (COLL) Q3 earnings: what to expect
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) will be announcing earnings results this Thursday before the bell. Here’s what investors should...
Via StockStory · November 3, 2026
Pfizer (PFE) Q3 2026 Earnings Call Transcriptfool.com
Pfizer lifts guidance as newer drugs grow, even as COVID sales keep falling.
Via The Motley Fool · November 3, 2026
BioNTech Q3 Earnings Call Highlightsmarketbeat.com
BioNTech (NASDAQ:BNTX) reported third-quarter 2026 revenue of €1.3 billion, down from €1.5 billion a year earlier, as lower demand for its COVID-19 vaccine weighed on results. The company raised the midpoint of its full-year revenue outlook while highlighting progress across its late-stage oncology
Via MarketBeat · November 3, 2026
Most Active S&P 500 Stocks: Oracle, Palantir, Marvell Lead Nov. 3 Volumechartmill.com
Via Chartmill · November 3, 2026
Pfizer's Eliquis Price Gains Cover COVID Drop: Rapid Earnings Reactionfool.com
Pfizer's revenue didn't grow, but the mix underneath it changed a lot.
Via The Motley Fool · November 3, 2026
Pfizer Beats Expectations in Q3 and Raises Its Guidance. Is the Stock Due for a Big Rally?fool.com
The healthcare stock may finally have the catalyst that it needs to take off before the end of the year.
Via The Motley Fool · November 3, 2026
Pfizer (NYSE:PFE) reports strong Q3 2026, full-year outlook slightly exceeds expectations
Global pharmaceutical company Pfizer (NYSE:PFE) reported Q3 2026 results exceeding the market’s revenue expectations, but revenue was flat year on year at $1...
Via StockStory · November 3, 2026
Pfizer Hikes Guidance On Solid Third Quarter, Names Company Vet As New CFOinvestors.com
Pfizer stock slipped a fraction early Tuesday, but the company raised its guidance for the year and named a new CFO.
Via Investor's Business Daily · November 3, 2026
Pfizer Reports Strong Third-Quarter 2026 Results And Raises 2026 Guidance
Pfizer Inc. (NYSE: PFE) reported financial results for the third quarter of 2026 and raised its full-year 2026 guidance(2) for both Revenues and Adjusted(3) diluted EPS.
By Pfizer Inc. · Via Business Wire · November 3, 2026
Pfizer Appoints Cecile Guegan as Chief Financial Officer
Pfizer Inc. (NYSE: PFE) today announced that its Board of Directors has unanimously appointed Cecile Guegan as Chief Financial Officer and Executive Vice President, effective November 1, 2026. Cecile has served as interim Chief Financial Officer since August 16, 2026, steering the company’s financial operations, execution and strategic planning.
By Pfizer Inc. · Via Business Wire · November 3, 2026
Most Active S&P 500 Stocks: Oracle, Ford, AT&T Lead Volumechartmill.com
Via Chartmill · November 2, 2026
Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digitsmarketbeat.com
Panama City, Guanacaste in Costa Rica and Lagos, Portugal top one investor's list for rental income and long-term growth, with Portuguese mortgages from 2.6%.
Via MarketBeat · November 2, 2026
Here's Why I Think Every Investor Needs to Invest in These "Miracle" Drugsfool.com
The market for GLP-1 drugs is forecast to explode. It may be understated still.
Via The Motley Fool · November 2, 2026
Corporate headshot photographer NYC Michael Benabib recently recognized for his work in a one-man show in Tokyo
NEW YORK, NY - November 2, 2026 - Michael Benabib, the corporate headshot photographer in New York City behind Executive Photos NYC, is expanding studio and on-location executive portrait sessions that apply the editorial approach he developed photographing for Forbes, The New York Times, Vanity Fair and The Wall Street Journal. As a corporate headshot photographer in New York City for more than 30 years, Benabib now photographs Fortune 500 executives, attorneys, physicians and full leadership teams on location and at his studio at 275 Fifth Avenue in Midtown Manhattan.
Via AB Newswire · November 2, 2026
1 healthcare stock with impressive fundamentals and 2 we ignore
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Shareholders who bet on the industry have been rewarded lately as...
Via StockStory · November 1, 2026
What to expect from Pfizer’s (PFE) Q3 earnings
Global pharmaceutical company Pfizer (NYSE:PFE) will be reporting results this Tuesday before market open. Here’s what to expect. Pfizer beat analysts’ reven...
Via StockStory · November 1, 2026
Pfizer Just Hit a 52-Week High. Is the Turnaround Finally Real?fool.com
Pfizer's post-COVID comeback is still only in the early stages.
Via The Motley Fool · October 31, 2026
S&P 500 Most-Active Stocks: Oct. 30, 2026chartmill.com
Via Chartmill · October 30, 2026
What Regeneron Pharmaceuticals (REGN) Said on Its Q3 Earnings Callmarketbeat.com
Regeneron Pharmaceuticals (NASDAQ:REGN) reported third-quarter 2026 revenue growth of 36% year over year to $5.1 billion, while non-GAAP diluted earnings per share rose 70% to $20.07. The company attributed the performance to increased Sanofi collaboration revenue and continued growth from DUPIXENT,
Via MarketBeat · October 30, 2026